TH136244A - High blood fat relieving agents and anemia relieving ingredients Elements to reduce uric acid levels and beverage and food products. - Google Patents
High blood fat relieving agents and anemia relieving ingredients Elements to reduce uric acid levels and beverage and food products.Info
- Publication number
- TH136244A TH136244A TH1201003026A TH1201003026A TH136244A TH 136244 A TH136244 A TH 136244A TH 1201003026 A TH1201003026 A TH 1201003026A TH 1201003026 A TH1201003026 A TH 1201003026A TH 136244 A TH136244 A TH 136244A
- Authority
- TH
- Thailand
- Prior art keywords
- relieving
- substance
- anemia
- beverage
- adjusting agent
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 7
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title 1
- 208000007502 anemia Diseases 0.000 title 1
- 235000013361 beverage Nutrition 0.000 title 1
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 235000013305 food Nutrition 0.000 title 1
- 239000004615 ingredient Substances 0.000 title 1
- 229940116269 uric acid Drugs 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract 8
- 230000003579 anti-obesity Effects 0.000 claims abstract 6
- 235000021588 free fatty acids Nutrition 0.000 claims abstract 6
- 230000007935 neutral effect Effects 0.000 claims abstract 6
- 235000012000 cholesterol Nutrition 0.000 claims abstract 4
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 claims abstract 3
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 claims abstract 3
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000003607 modifier Substances 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 241000269350 Anura Species 0.000 claims 1
- PVLHOJXLNBFHDX-XHJPDDKBSA-N Panaxadiol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(CC[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 PVLHOJXLNBFHDX-XHJPDDKBSA-N 0.000 claims 1
- SYFJYASKXNAXKC-UHFFFAOYSA-N Panaxadiol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CCC34C SYFJYASKXNAXKC-UHFFFAOYSA-N 0.000 claims 1
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 claims 1
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- OORMXZNMRWBSTK-UHFFFAOYSA-N dammaran Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC(C(C)CCCC(C)C)C4CCC3C21C OORMXZNMRWBSTK-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 claims 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract 8
- RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical compound OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 abstract 2
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 2
- 229930182490 saponin Natural products 0.000 abstract 2
- 150000007949 saponins Chemical class 0.000 abstract 2
Abstract
DC60(20/06/55) สารปรับปริมาณไขมันที่มีสมบัติเป็นกลางสารปรับปริมาณคลอเรสเตอรอลสารปรับปริมาณ กรดไขมันอิสระและสารต้านความอ้วนซึ่งมีลักษณะจำเพาะในการที่อย่างน้อยมีโปรโตแพนแนกซาตริ ออลแพนแนกซาตริออลโปรโตแพนแนกซาไดออลและแพนแนกซาไดออลอย่างน้อยชนิดใดชนิดหนึ่ง ซึ่งเป็นเอไกลโคนของซาโปนินชนิดแดมมาแรนผสมอยู่และสารบรรเทาโรคไขมันในโลหิตสูงซึ่งมี ลักษณะจำเพาะในการที่อย่างน้อยมีสารปรับปริมาณไขมันที่มีสมบัติเป็นกลางนี้สารปรับปริมาณคลอ เรสเตอรอลนี้สารปรับปริมาณกรดไขมันอิสระนี้และสารต้านความอ้วนนี้ชนิดใดชนิดหนึ่งผสมอยู่ สารปรับปริมาณไขมันที่มีสมบัติเป็นกลางสารปรับปริมาณคลอเรสเตอรอลสารปรับปริมาณ กรดไขมันอิสระและสารต้านความอ้วนซึ่งมีลักษณะจำเพาะในการที่อย่างน้อยมีโปรโตแพนแนกซาตริ ออลแพนแนกซาตริออลโปรโตแพนแนกซาไดออลและแพนแนกซาไดออลอย่างน้อยชนิดใดชนิดหนึ่ง ซึ่งเป็นเอไกลโคนของซาโปนินชนิดแดมมาแรนผสมอยู่และสารบรรเทาโรคไขมันในโลหิตสูงซึ่งมี ลักษณะจำเพาะในการที่อย่างน้อยมีสารปรับปริมาณไขมันที่มีสมบัติเป็นกลางนี้สารปรับปริมาณคลอ เรสเตอรอลนี้สารปรับปริมาณกรดไขมันอิสระนี้และสารต้านความอ้วนนี้ชนิดใดชนิดหนึ่งผสมอยู่ DC60(20/06/12) Fat adjusting agent with neutral properties. Cholesterol adjusting agent. Free fatty acids and anti-obesity substances which are characterized by at least the presence of protopanaxatri. at least one of all pannaxatriol, protopanaxadiol and pannaxadiol. which is a glycone of damaran saponin mixed in and a substance that relieves hypercholesterolemia which has The specification is that at least there is a fat adjusting agent that has neutral properties. This resterol, this substance that adjusts the amount of free fatty acids, and this type of anti-obesity substance are mixed in. Neutral fat adjusting agent, cholesterol adjusting agent, Free fatty acids and anti-obesity substances which are characterized by at least the presence of protopanaxatri. at least one of all pannaxatriol, protopanaxadiol and pannaxadiol. which is a glycone of damaran saponin mixed in and a substance that relieves hypercholesterolemia which has The specification is that at least there is a fat adjusting agent that has neutral properties. This resterol, this substance that adjusts the amount of free fatty acids, and this type of anti-obesity substance are mixed in.
Claims (2)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH136244A true TH136244A (en) | 2014-08-27 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kawiak et al. | Plumbagin induces apoptosis in Her2-overexpressing breast cancer cells through the mitochondrial-mediated pathway | |
| GEP20166457B (en) | Low-oil pharmaceutical emulsion compositions comprising progestogen | |
| WO2011018501A3 (en) | Composition including an unsaponifiable fraction | |
| MX2019013426A (en) | SALTS OF BERBERINE, SALTS URSODESOXICOLICAS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION OF THE SAME. | |
| JO3813B1 (en) | Novel fatty acids and their use in conjugation to biomolecules | |
| AR084932A1 (en) | OPHTHALMIC COMPOSITION INCLUDING AN ANDROGEN AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF AN EYE DISEASE RESULTING FROM AN ANDROGENIC DEFICIENCY | |
| WO2009046446A3 (en) | Dendrimers for sustained release of compounds | |
| NZ618734A (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
| EP2444491A3 (en) | Hyperglycosylated human coagulation factor IX | |
| WO2007121352A3 (en) | Therapeutic triterpenoids | |
| WO2008058547A3 (en) | Alpha-lactalbumin composition | |
| BRPI0820068B8 (en) | use of a yeast strain and/or a composition comprising a yeast strain for preparing a medicament | |
| EA200970840A1 (en) | LIQUID HERBICID PREPARATIONS BASED ON SULPHONYLMOLOVEV | |
| HK1247856A1 (en) | Hydroxypropyl beta-cyclodextrin compositions and methods | |
| EP4410833A3 (en) | Compositions and methods for treating fatty tissue buildup | |
| WO2011058245A8 (en) | Novel mannopyranoside derivatives with anticancer activity | |
| WO2011031063A3 (en) | Composition for preventing or treating metabolic disorders, containing the anti-4-1bb antibody | |
| WO2010042701A3 (en) | Corticosteroid compositions for use in treating diseases of the upper and lower airway passages | |
| JP2020193227A (en) | Topical composition | |
| HRP20161147T1 (en) | PHARMACEUTICAL COMPOSITION AND PROCEDURE OF ITS MANUFACTURING | |
| CN105232525A (en) | Hypolipidemic drug combination and application thereof | |
| WO2009012784A3 (en) | Methods for preparing cytotoxic complexes of emulsifier and fatty acid | |
| WO2010119366A3 (en) | A medicinal cream made using fluticasone propionate, and chitosan, and a process to make the same | |
| US10568925B2 (en) | Extracts of Curcuma amada and uses thereof | |
| WO2010119367A3 (en) | A medicinal cream made using hydrocortisone acetate and a process to make the same |